Kornimate/medical-research-clean huggingface dataset:
hypofractionated brain radiation in egfr mutated adenocarcinoma cranial disease (hybrid)

Conditions: Stage IV EGFR Mutated NSCL With Brain Metastases

Summary: a multi-center phase iii randomized controlled study to evaluate the efficacy of hypofractionated srs (hfsrs) along with egfr-tki in patients with brain metastasis from non-small cell lung cancer (nsclc). assuming that hfsrs is not inferior to egfr-tki concurrent with whole brain radiotherapy (wbrt), the primary end point is intracranial pfs (ipfs), while secondary outcomes included overall survival (os), evaluation of cognitive function, quality of life (qol) and adverse events.

wbrt remains to be standard of care for nscl patients. long term survival from wbrt may have noticeable cognitive dysfunction. the egfr tki has reasonable control for intracranial disease, but the duration of egfr tki control disease is variable due to tendency of drug resistance. to maintain intracranial disease control and improve cognitive function, the investigators propose using hypofractionated srs in multiple brain metastases or large brain lesions alone with tki.

Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of non-small cell lung cancer (nsclc); * diagnosis of brain metastases on a gadolinium-enhanced mri. * more than 3 sites of intracranial metastases, or the longest diameter of the intracranial lesion is more than 4 cm. * positive egfr mutation. * life expectancy ≥3months. * have one or more measurable encephalic lesions according to recist. * adequate hematological function: absolute neutrophil count (anc) ≥1.5 x 109/l, and platelet count ≥100 x 109/l. * adequate renal function: serum creatinine ≤1.5 x uln, or ≥ 50 ml/min. * adequate liver function: total bilirubin ≤ 1.5 x upper limit of normal (uln) and alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< 2.5 x uln in the absence of liver metastases, or \< 5 x uln in case of liver metastases. * female subjects should not be pregnant. * all human subjects should able to comply with the required protocol and follow-up procedures, and able to receive oral medications. * written informed consent provided. exclusion criteria: * previous usage of egfr-tki or antibody to egfr: gefitinib, erlotinib, herceptin, erbitux. * csf or mri findings consistent with metastases of spinal cord, meninges or meningeal. * allergic to icotinib. * lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease. * pregnancy or breast-feeding women. * participate in the other anti-tumor clinical trials in 4 weeks.
hydroxyephedrine pet/ct in sympathetic nervous system disease

Conditions: Sympathetic Nervous System Diseases; Sympathetic Nervous Structure Injury; Sympathetic Nerve Injury

Summary: to evaluate the potential usefulness of 11c/18f-hed positron emission tomography/ computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various tau-related disease patients.

subjects with various sympathetic nerves-related disease patients underwent 11c/18f-hed pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 11c/18f-hed pet/ct were calculated.

Eligibility criteria:
inclusion criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled hed pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: pet/ct mri hydroxyephedrine
nocturnal insulin-glucose in hospital: tight control

Conditions: Type 1 Diabetes

Summary: the aim of the study is to assess the efficacy and safety of a closed-loop system consisting of a predictive rule-based algorithm integrated on the medtronic portable glucose control system (pgcs) in patients with type 1 diabetes for controlling the nocturnal and post-breakfast periods. intervention will be to apply the automated closed-loop system by administering a subcutaneous insulin microbolus every 5 minutes depending on reading from a continuous glucose measurement (cgm) system.


Eligibility criteria:
inclusion criteria: * type 1 diabetes * diabetes duration \> 3 years * continuous subcutaneous insulin infusion (csii) treatment for more than 1 year * a1c 6-9% * no ketoacidosis during the previous 12 months * glomerular filtration rate (gfr) \> 60 ml/kg/min m2 * willingness of participate and signed and dated written informed consent in accordance with good clinical practice exclusion criteria: * gastroparesis * hypoglycemia unawareness * uncorrected visual impairment * deafness * bmi\> 35 kg/m2
screening in oculopharyngeal muscular dystrophy

Conditions: Oculopharyngeal Muscular Dystrophy

Summary: oculopharyngeal muscular dystrophy (opmd) is a rare myopathic disease that results in progressive degeneration of the oral and pharyngeal muscular, resulting in severe dysphagia and dysarthria. opmd is considered a rare disease; therefore, limited research is available on the natural progression of the disease or the utility of biomarkers to identify swallowing impairment. the aim of this study is: 1. to identify accurate, reliable and non-invasive clinical markers of swallowing impairment 2. to determine the discriminate ability of these markers to identify impairments in swallow safety and swallowing efficiency.

participants will be recruited from the neurology clinic at the university of florida. the single evaluation will occur in the pis research laboratory at the university of florida, gainesville, florida.

Eligibility criteria:
inclusion criteria: * diagnosis of oculopharyngeal muscular dystrophy * no allergies to barium or capsaicin, * no tracheotomy or mechanical ventilation * no significant concurrent respiratory disease (e.g., copd). exclusion criteria: * pregnant women

Keywords: screening opmd dysphagia dysarthria
ams advance and advance xp male sling systems for the treatment of stress urinary incontinence following prostatectomy: evaluation of safety, efficacy, and quality of life through retrospective chart review and prospective follow-up

Conditions: Urinary Incontinence, Stress; Intrinsic Sphincter Deficiency

Summary: a single-center retrospective chart review of advance and advance xp subject data, combined with prospective follow-up of the same subjects to confirm continence, adverse event, and quality of life status. this study includes patients previously implanted with an advance or advance xp male sling.

a single-center retrospective chart review of advance and advance xp subject data, combined with prospective follow-up of the same subjects to confirm continence, adverse event, and quality of life status. this study includes patients previously implanted with an advance or advance xp male sling.

Eligibility criteria:
inclusion criteria: 1. valid, written informed consent has been obtained 2. male subject ≥40 years of age who received the advance male sling after january 1, 2010 or the advance xp male sling after july 1, 2010 for the treatment of post prostatectomy sui 3. pad use of 1 to 8 pads per day prior to sling placement (subjects who used only a dry prophylactic pad or safety liner at baseline will not be included) 4. external (distal) sphincter contractility and a coaptive zone of ≥ 1cm confirmed by endoscopic view prior to sling placement 5. primary etiology of sui resulting from radical prostatectomy including, simple open prostatectomy, robotic or laparoscopic prostatectomy exclusion criteria: 1. pad use of more than 8 pads per day prior to sling placement for incontinence management 2. urine loss while lying in bed prior to sling placement 3. treatment with a urethral sling system, an ams sphincter 800®, or any implanted device for the treatment of urinary incontinence (not including bulking agents) prior to sling placement 4. turp procedure prior to sling placement 5. urge predominant incontinence prior to sling placement 6. past or current neurological disorder (e.g. neurogenic bladder, multiple sclerosis, parkinson's disease) 7. history of connective tissue or autoimmune conditions 8. past or current condition of compromised immune system 9. placement of an inflatable penile prosthesis (ipp) after sling placement 10. post void residual of \>50 ml prior to sling placement

Keywords: male incontinence advance male sling advance xp male sling male sling
therapeutic riding and neuromuscular disease

Conditions: Neuromuscular Disease

Summary: the purpose of this current prospective study is to assess the effects of a therapeutic riding exercise program conducted in patients suffering from neuromuscular disease. the exercise intervention aims at improving gross motor function, gross motor performance, balance, spasticity, posture and quality of life. patients were randomized according to age, sex, mental ability and gross motor function. furthermore, patients will be subdivided into categories of central nervous system (brain/ spinal cord) and peripheral (peripheral nerve or muscle) diseases. the exercise program duration will be 12 weeks, once a week with 30-40 minutes sessions. six measurements will be conducted: the gross motor function measure, the gross motor performance measure, the quality of life questionnaire for children, the pediatric balance scale, the dynamic plate in combination with x-ray for posture control, the modified ashworth scale for spasticity and the wisc 3 for mental ability. the results will be collected and evaluated using the statistical programme spss.


Eligibility criteria:
inclusion criteria: * children with neuromuscular disease * parental consent * sitting posture capability * hip abduction capability on horseback * ability to communicate and collaborate with the researcher exclusion criteria: * children with scheuermann disease * uncontrolled seizures (a) child with generalized seizure over 2 minutes in the last three months (b) children who are not well-adjusted levels of antiepileptic drugs. * musculoskeletal disorder that may be aggravated by the movement of the horse such as atlantoaxial instability, osteoporosis etc. * scoliosis \> 30 degree * allergy to dust

Keywords: cerebral palsy brain injury spinal cord injuries muscular disease
an unusual association between pancreatic cancer and purtscher-like retinopathy

Conditions: Purtscher Retinopathy; Pancreatic Cancer

Summary: an unusual association between pancreatic cancer and purtscher-like retinopathy

purtscher's retinopathy may cause sudden loss of vision of varying severity, secondary to head or chest injury. its pathophysiology is unclear. purtscher's-like retinopathy has more attenuated clinical and objective features and can be associated with many non-neoplastic pathologies. otherwise, an association of this kind of retinopathy with malignancies has been described once in the literature (multiple myeloma). we present a case report on a unique association between pancreatic cancer and purtscher-type retinopathy.

Eligibility criteria:
inclusion criteria: none - exclusion criteria: none -
heliox-driven racemic epinephrine in treatment of bronchiolitis in pediatric ed patients

Conditions: Bronchiolitis

Summary: the purpose of this study is to assess whether children with moderate to severe bronchiolitis treated with standard racemic epinephrine therapy via 70:30 helium-oxygen (heliox) driven nebulization will have improvements in measurements of airway more rapidly than those treated with conventional air-oxygen driven nebulization.


Eligibility criteria:
inclusion criteria: * any child 2-12 months old seen in the emergency department. * a clinical bronchiolitis score \> 3 by modified wood's clinical bronchiolitis score (m-wcbs). * diagnostic criteria of bronchiolitis includes tachypnea, cough, prolonged expiratory phase, wheezing, rales, chest retractions, and hyperinflation of lungs on chest radiograph. after consenting a patient to the study, respiratory syncytial virus (rsv) infection will be tested by rapid enzyme-linked immunoabsorbent assay of nasal secretions. exclusion criteria: * no child will be excluded based on race or gender * patients under the age of 2 months or greater than 12 months * patients with cyanotic heart disease * patients with lobar pneumonia, defined by results of chest radiographs. * the presence of interstitial disease or diffuse patchy marking consistent with atelectasis on chest radiographs will not exclude patients. * patients with croup. * patients with foreign body aspiration. * patients with history of cystic fibrosis, bronchopulmonary dysplasia or other chronic lung disease. * patients with liver or renal disease. * patients with sickle cell anemia. * patients requiring mechanical ventilation. * patients who develop supraventricular tachycardia secondary to racemic epinephrine administration. * patients with tracheomalacia or bronchomalacia. * patients who had received bronchodilators within 2 hours of initiation of the study. * patients who had received systemic corticosteroids within 72 hours of enrollment * patients who suffered from persistent airway hyperreactivity in the 3 months before the study. * patients who do not tolerate the nasal cannulae for 45 out of 60 minutes.

Keywords: heliox bronchiolitis racemic epinephrine
safety and efficacy of andecaliximab (gs-5745) in adults with moderately to severely active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the primary objectives of this study are as follows: 1) to evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (ebs) clinical remission at week 8 (cohort 1); 2) to evaluate the efficacy of andecaliximab to maintain ebs clinical remission at week 52 (cohort 2); and 3) to evaluate the safety and tolerability of andecaliximab. the study will consist of 3 parts: induction phase (cohort 1), maintenance phase (cohort 2), and an optional extended treatment phase.


Eligibility criteria:
key inclusion criteria: * ulcerative colitis (uc) confirmed on endoscopy * moderately to severely active uc (mayo score 6-12) * may be receiving oral 5-aminosalicylate (asa), oral corticosteroid, azathioprine, 6-mercaptopurine (mp), or methotrexate * treatment failure with at least one of the following agents received: corticosteroids, immunomodulators, tumor necrosis factor-alpha (tnfα) antagonists, vedolizumab key exclusion criteria: * diagnose of crohn's disease or indeterminate colitis * pregnant or lactating females * any chronic medical condition (including, but not limited to cardiac or pulmonary disease, alcohol or drug abuse) * exhibit severe uc / clinically significant active infection * history of malignancy in the last 5 years note: other protocol defined inclusion/exclusion criteria may apply.
to evaluate safety and efficacy of autologous cd19 chimeric antigen receptor (car)-t cells in relapsed/refractory b- non-hodgkin lymphoma (b-nhl)

Conditions: Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma

Summary: a phase ii open-label single-arm study to evaluate safety and efficacy of locally manufactured autologous cd19-directed car t-cells in patients with relapsed/refractory b- non-hodgkin lymphoma (b-nhl) or patients not eligible for hematopoietic stem cell transplantation (hct)


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed diagnosed with cd19 positive b cell nhl in accordance with who classification * patients who are refractory to second-line treatment or patients who relapsed after first-line treatment with no available curative options such as autologous or allogeneic haematopoietic stem cell transplantation (hsct) or relapse within one year of autologous hsct * at least one measurable lesion according to revised iwg response criteria * age between ≥13to ≤75 years * adequate organ function as defined by a creatinine clearance \>40 ml/min, serum alanine transaminase (alt) \ 45% * absolute neutrophil count ≥ 1500/μl, haemoglobin level ≥ 7 g/dl, platelets ≥ 50000/μl. * life expectancy \>12 weeks * eastern cooperative oncology group (ecog) performance status ≤ 2 * female of childbearing age must have a negative pregnancy test and is on two effective contraception methods * male patients must use two effective contraception methods exclusion criteria: * active central nervous system (cns) lymphoma (detected by imaging study or cerebrospinal fluid (csf) analysis) * active cancer(other than nhl) or receiving cancer treatment * evidence of severe lung, heart (new york heart association class iii/iv, arrhythmia, heart block, uncontrolled hypertension), liver, or renal failure or severe neurologic disorder * presence of active autoimmune disease requiring immunosuppressive therapy * human immunodeficiency virus (hiv) positivity * active hepatitis b, and hepatitis c infection * uncontrolled infection * pregnant/nursing female. * receiving autologous or allogeneic stem cell transplant within 12 weeks of enrolment

Keywords: rr b- nhl cd19 car-t cells malaysia
beat1d: benign autoimmunity and type 1 diabetes

Conditions: Type 1 Diabetes

Summary: national multi-center non-interventional case-control cohort study with collection of biological samples to characterize the autoimmune t and b lymphocytes involved in the development of type 1 diabetes.

the overall objective of this study is to define the differential characteristics of autoimmune t and b lymphocytes across individuals with t1d, other forms of diabetes or autoimmunity, and no disease. the hypothesis is that the characterization of the autoimmune t and b lymphocytes involved in t1d development may allow us to clarify the pathophysiological mechanisms of disease and to identify novel biomarkers for diagnostic, prognostic and therapeutic follow-up applications.

Eligibility criteria:
inclusion criteria: 1. type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin therapy started within 6 months from clinical onset; and/or the presence of at least one anti-islet auto-antibody. 2. other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g. type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or other autoimmune endocrinopathies, isolated or multiple. 3. no diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor, infectious or immune pathologies, or other conditions related to autoimmune or metabolic alterations that may bias the variables under study. 4. lymphadenectomy planned in the frame of an abdominal surgery: pancreatic lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of an underlying condition. exclusion criteria: for all participants: ongoing pregnancy; known hiv/hcv infection; absence of social security coverage; placement under judicial protection; absence of signature of the informed study consent.

Keywords: type 1 diabetes autoimmunity lymphocytes beta cells biomarkers
probiotics effect on glucose and lipid metabolism and gut microbiota in patients with obesity

Conditions: Obesity

Summary: the purpose of this study is to determine whether the probiotics will be effective in the treatment of obesity

this study aims to evaluate the effect of probiotics on the improvement of glucose and lipid metabolism, as well as the gut microbiota.baseline, 1 month and 3 months data will be collected and put into analysis to provide some suggestions on the probiotics use in the clinical practice for obesity patients.

Eligibility criteria:
inclusion criteria: 1. age 15-60 years 2. bmi≥28.0kg/m2 3. agree to cooperate in the trial 4. provision of written informed consent exclusion criteria: 1. with chronic gastrointestinal diseases, severe immune deficiency, lactose intolerance 2. diabetes 3. use antibiotics, bacteriostatic agents (eg berberine), lipid-lowering drugs, antacids, h2 blockers, proton pump inhibitors, corticosteroids or sex hormones 4. use any probiotics in the last 3 months 5. allergic constitution 6. participating in any other clinical trials 7. was not able to insist until the end 8. pregnant and lactating women

Keywords: obesity,probiotics,treatment
therapeutic strategies in acromegalic subjects treated with lanreotide 120mg

Conditions: Acromegaly

Summary: the study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to describe the modalities and the global effectiveness of alternative strategies.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or more, suffering from acromegaly * treatment naïve or treated subject (whatever the previous treatments except lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. requiring a treatment with somatostatin analog (ssa) * having performed a magnetic resonance imaging (mri) to evaluate the tumor size within the previous 12 weeks (post-surgery mri for operated subjects) * in whom the physician has already decided to initiate a treatment with lanreotide 120mg as a monotherapy exclusion criteria: * subject previously/currently treated with lanreotide 120mg * history of radiotherapy for acromegaly * subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression * concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists * active neoplastic disease
effects of maitland's antero-posterior versus lateral mobilizations on cardiovascular responses

Conditions: Neck Pain

Summary: this study will be a randomized control trial and will be conducted in polyclinic hospital islamabad \& rawal dental and general hospital rawalpindi. a sample of 62 participants will be taken. patients will be divided into two equal groups of 31 participants in each group, group randomization will be done through flip coin method. patients in group a will receive maitland's antero-posterior mobilization, while patients in group b will receive maitland's lateral mobilizations. 4 sessions of treatment will be given for 2 weeks with interval of 3 days, 4 days and 7 days between 1st \& 2nd session, 2nd \& 3rd session and 3rd \& 4th session, respectively. the outcome measures will be omron automatic blood pressure monitor, numeric pain rating scale(nprs) and global rating of change questionare will be measured at baseline and at the end of 4th session. data will be analyzed by spss 25.


Eligibility criteria:
inclusion criteria: * participants falling in this category would be recruited into the study. * age 25 to 55 years * pain in neck with no known cause for \> 3 months * resting systolic blood pressure between 90 to 139 mmhg * resting diastolic blood pressure between 60 to 88 mmhg * resting heart rate between 60 to 100 beats/min * no prior exposure to antero-posterior and lateral mobilizations exclusion criteria: * participants falling in this category would be excluded from the study. * age \ 55 * current smokers * history of fainting spells, diabetes mellitus, spinal surgery and whiplash injury( in last 6 months) * taking medications for blood thinning, diabetes mellitus * having neurologic or cardiovascular disease, radiating pain, cervicogenic headaches * movement coordination impairment * athletes * unable to read and write

Keywords: maitland mobilization